2020-10-29 OMA Agenda - Board of Trustees

Advised against the off-label use of medications approved for other disease states for the sole purpose of producing weight loss. The modality and intensity of obesity interventions should be based on the primary, secondary, and tertiary phases of disease prevention. All adults should be screened annually using BMI measurement; in most populations a cut- off of ≥25 kg/m 2 should be used to initiate further evaluation of overweight or obesity. Clinical judgement must be used when BMI is employed as the anthropometric measure of excess adiposity. Patients with overweight or obesity and patients experiencing progressive weight gain should be screened for weight-related complications (T2DM dyslipidemia, hypertension, cardiovascular disease, nonalcoholic fatty liver disease and steatohepatitis, PCOS, female infertility, male hypogonadism, OSA, asthma/reactive airway disease, osteoarthritis, urinary stress incontinence, GERD, depression). This guideline recommends goals for weight loss that may be beneficial in patients with weight-related complications, the recommended weight loss ranges from 5-40% depending on the complication. A structured lifestyle intervention program designed for weight loss (lifestyle therapy) and consisting of a healthy meal plan, physical activity, and behavioral interventions should be available to patients who are being treated for overweight or obesity. Pharmacotherapy for overweight and obesity should be used only as an adjunct to lifestyle therapy and not alone.

American Association of Clinical Endocrinologists and American College of Endocrinology 9

2016

Clinical Practice Guideline

Comprehensive medical care plan for obesity

28